Melnick David A. 4
4 · Spero Therapeutics, Inc. · Filed Jan 2, 2019
Insider Transaction Report
Form 4
Melnick David A.
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2019-01-02+65,000→ 65,000 totalExercise: $6.26Exp: 2029-01-02→ Common Stock (65,000 underlying)
Footnotes (1)
- [F1]The shares underlying this option vest as to 25% on January 2, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.